Solas BioVentures

Excited to be part of #LSTCON2024 in Nashville! With Isaiah Reeves, PhD (where we met just last year!). It's an incredible event bringing together industry leaders to drive innovation and celebrate breakthroughs in #pharma, #meddevice, #diagnostics, and more. This year, I’m honored to serve as a judge for the pitch competition, where we’ll spotlight some of the most promising innovations shaping the future of life sciences. Looking forward to connecting with peers, exchanging ideas, and championing groundbreaking solutions in the industry. Thank you to Life Science Tennessee for organizing such an impactful event and to the sponsors who make it possible. Let’s make this a memorable experience! #Innovation #LifeSciences #Leadership

The Digital Health Applications (DiGAs) framework is revolutionizing how digital health technologies are brought to market in Europe. But how is this evolving, and what does it mean for Healthtech companies looking to succeed in the European market? In our upcoming LSI Europe ‘24 panel, "The DiGAs Framework, and the Evolution of Getting Healthtech to Market in Europe," we’ll explore this framework in depth. Our panelists will discuss the opportunities and challenges presented by DiGAs, how the framework is shaping market entry strategies, and what this means for the future of Healthtech innovation in Europe. Featured Panelists: • Samantha J. — Elaia Partners • Martin Müller — CARMA FUND Management GmbH • Laurent Pacheco, MD MBA PhD (Econ.) — Solas BioVentures • Amine Benmoussa — Karista Join us at LSI Europe ‘24 this September 16-20th to see more panel sessions like this and connect with hundreds of global Medtech and Healthtech leaders in Sintra, Portugal. Apply on our website today while space is still available.

We are thrilled to share that our Managing Partner David Adair, will be participating in a panel at LSI Europe '24. He will be joined by our portfolio company CEO, Robert Krummen of Vektor Medical, Inc., along with esteemed co-investors Luc Marengere from TVM Capital Life Science, Ashley Seehusen from SANTÉ, and Alexander Goemans CFO at Xeltis. The discussion will focus on "Building Syndicates of Cross-Border Investors in Medtech Companies." Will you be attending? Let us know - we'd love to connect! #LSIEurope24 #LSIAlumni #Medtech #LifeSciences #MedicalTechnology #VentureCapital #HealthTech

Congrats to Francis Medical for treating their 100th patient!

Solas BioVentures is both excited and honored to partner with outstanding pioneers like Professors Shahid Nimjee and Bruce Sullenger on a potential groundbreaking effort. The Basking effort targets a different clot mechanism allowing for longer therapeutic windows versus traditional clot "busters", but more importantly, the other half of the equation, a specifically designed reversal agent. Balance in therapy and life is most important. Congratulations to CEO Rich Shea for leading the transfer from a lab to bedside clinical trials. Both Solas and myself are excited to work with an incredible cast of management, syndicate partners, and fellow board directors led by the incredible talent Steve Gillis. Solas believes it is "game on " for a thrombotic stroke care revolution! Stroke is a top 3 killer, for me, it is number one, my favorite grandfather died while I was a beginning 4th year medical student. That tailspin took a while to recover from, it is my sincere belief and hope that one day soon, that might not be a daily recurrent scene for other families. Anchors away Basking. Thank you NeuroNews.

Exciting news from Vektor Medical, Inc.! The Solas BioVentures team partnered with TVM Capital Healthcare to co-lead the latest round for $16 million in Series A funding to continue developing their innovative arrhythmia analysis tool, vMap. vMap uses artificial intelligence to help doctors improve outcomes for patients with atrial fibrillation. This technology has the potential to make a real difference in the lives of many people, and I'm excited to see how it develops. If you're interested in learning more about Vektor Medical and their mission to improve patient care, I encourage you to check out their website or connect with them on LinkedIn. #VektorMedical #AI #Healthcare #AtrialFibrillation #Investment

Today, Vektor Medical, Inc. announced a $16 million Series A investment, co-led by Solas BioVentures and TVM Capital Life Science. This funding helps further advance our mission to revolutionize arrhythmia care through cutting-edge, non-invasive AI-based technology. Proud to be a part of the Vektor Medical team! #epeeps #healthcareinnovation #atrialfibrillation #arrhythmia #aiadvancements